Current Nanomedicine for Targeted Vascular Disease Treatment: Trends and Perspectives
Abstract
:1. Introduction
2. Properties of NPs for Targeted Drug Delivery and Types of NPs Used for CVD
2.1. Organic NPs
2.1.1. Lipid-Based NPs
2.1.2. Dendrimers
2.2. Inorganic NPs
2.2.1. Carbon-Based NPs
2.2.2. Metal NPs
2.3. Organic–Inorganic NPs
3. Biological Markers in CVDs for Targeted Nanomedicine
4. Strategies for Targeted Nanomedicine for CVDs
4.1. Passive Targeting
4.2. Active Targeting
5. Challenges and Future Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bonetti, P.O.; Lerman, L.O.; Lerman, A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 168–175. [Google Scholar] [CrossRef] [PubMed]
- Malakar, A.K.; Choudhury, D.; Halder, B.; Paul, P.; Uddin, A.; Chakraborty, S. A review on coronary artery disease, its risk factors, and therapeutics. J. Cell. Physiol. 2019, 234, 16812–16823. [Google Scholar] [CrossRef] [PubMed]
- Geovanini, G.R.; Libby, P. Atherosclerosis and inflammation: Overview and updates. Clin. Sci. 2018, 132, 1243–1252. [Google Scholar] [CrossRef] [PubMed]
- Cho, J.G.; Lee, A.; Chang, W.; Lee, M.-S.; Kim, J. Endothelial to Mesenchymal Transition Represents a Key Link in the Interaction between Inflammation and Endothelial Dysfunction. Front. Immunol. 2018, 9, 294. [Google Scholar] [CrossRef] [Green Version]
- Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2045–2051. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Libby, P. Vascular biology of atherosclerosis: Overview and state of the art. Am. J. Cardiol. 2003, 91, 3–6. [Google Scholar] [CrossRef]
- Lusis, A.J. Atherosclerosis. Nature 2000, 407, 233–241. [Google Scholar] [CrossRef] [PubMed]
- Villa-Roel, N.; Ryu, K.; Jo, H. Role of Biomechanical Stress and Mechanosensitive miRNAs in Calcific Aortic Valve Disease. In Cardiovascular Calcification and Bone Mineralization; Aikawa, E., Hutcheson, J.D., Eds.; Springer International Publishing: Cham, Swizerland, 2020; pp. 117–135. [Google Scholar] [CrossRef]
- Sontheimer, D.L. Peripheral vascular disease: Diagnosis and treatment. Am. Fam. Physician 2006, 73, 1971–1976. [Google Scholar] [PubMed]
- Ghantous, C.M.; Kamareddine, L.; Farhat, R.; Zouein, F.A.; Mondello, S.; Kobeissy, F.; Zeidan, A. Advances in Cardiovascular Biomarker Discovery. Biomedicines 2020, 8, 552. [Google Scholar] [CrossRef]
- Stehlik, J.; Kobashigawa, J.; Hunt, S.A.; Reichenspurner, H.; Kirklin, J.K. Honoring 50 Years of Clinical Heart Transplantation in Circulation. Circulation 2018, 137, 71–87. [Google Scholar] [CrossRef]
- Zelniker, T.A.; Braunwald, E. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. J. Am. Coll. Cardiol. 2020, 75, 435–447. [Google Scholar] [CrossRef] [PubMed]
- Leopold, J.A.; Loscalzo, J. Emerging Role of Precision Medicine in Cardiovascular Disease. Circ. Res. 2018, 122, 1302–1315. [Google Scholar] [CrossRef]
- Ariel, H.; Cooke, J.P. Cardiovascular Risk of Proton Pump Inhibitors. Methodist DeBakey Cardiovasc. J. 2019, 15, 214–219. [Google Scholar] [CrossRef]
- Rossello, X.; Pocock, S.J.; Julian, D.G. Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. J. Am. Coll. Cardiol. 2015, 66, 1273–1285. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pala, R.; Anju, V.T.; Dyavaiah, M.; Busi, S.; Nauli, S.M. Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases. Int. J. Nanomed. 2020, 15, 3741–3769. [Google Scholar] [CrossRef]
- Chen, J.; Zhang, X.; Millican, R.; Sherwood, J.; Martin, S.; Jo, H.; Yoon, Y.-s.; Brott, B.C.; Jun, H.-W. Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis. Adv. Drug Deliv. Rev. 2021, 170, 142–199. [Google Scholar] [CrossRef] [PubMed]
- Germain, M.; Caputo, F.; Metcalfe, S.; Tosi, G.; Spring, K.; Åslund, A.K.O.; Pottier, A.; Schiffelers, R.; Ceccaldi, A.; Schmid, R. Delivering the power of nanomedicine to patients today. J. Control. Release 2020, 326, 164–171. [Google Scholar] [CrossRef]
- Ryu, K.; Park, J.; Kim, T.-i. Effect of pH-Responsive Charge-Conversional Polymer Coating to Cationic Reduced Graphene Oxide Nanostructures for Tumor Microenvironment-Targeted Drug Delivery Systems. Nanomaterials 2019, 9, 1289. [Google Scholar] [CrossRef] [Green Version]
- Hu, Q.; Fang, Z.; Ge, J.; Li, H. Nanotechnology for cardiovascular diseases. Innovation 2022, 3, 100214. [Google Scholar] [CrossRef]
- Kim, B.Y.S.; Rutka, J.T.; Chan, W.C.W. Nanomedicine. N. Engl. J. Med. 2010, 363, 2434–2443. [Google Scholar] [CrossRef] [Green Version]
- Irvine, D.J.; Dane, E.L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 2020, 20, 321–334. [Google Scholar] [CrossRef] [PubMed]
- Ryu, K.; Lee, M.K.; Park, J.; Kim, T.-i. pH-Responsive Charge-Conversional Poly (ethylene imine)–Poly (l-lysine)–Poly (l-glutamic acid) with Self-Assembly and Endosome Buffering Ability for Gene Delivery Systems. ACS Appl. Bio Mater. 2018, 1, 1496–1504. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Sharma, R.; Ryu, K.; Shen, P.; Salaita, K.; Jo, H. Conditional Antisense Oligonucleotides Triggered by miRNA. ACS Chem. Biol. 2021, 16, 2255–2267. [Google Scholar] [CrossRef] [PubMed]
- Matoba, T.; Egashira, K. Nanoparticle-Mediated Drug Delivery System for Cardiovascular Disease. Int. Heart J. 2014, 55, 281–286. [Google Scholar] [CrossRef] [Green Version]
- Sun, D.; Chen, J.; Wang, Y.; Ji, H.; Peng, R.; Jin, L.; Wu, W. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery. Theranostics 2019, 9, 6885–6900. [Google Scholar] [CrossRef] [PubMed]
- Pearce, A.K.; O’Reilly, R.K. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine. Bioconjugate Chem. 2019, 30, 2300–2311. [Google Scholar] [CrossRef]
- Lombardo, D.; Kiselev, M.A.; Caccamo, M.T. Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine. J. Nanomater. 2019, 2019, 3702518. [Google Scholar] [CrossRef]
- Gao, D.; Guo, X.; Zhang, X.; Chen, S.; Wang, Y.; Chen, T.; Huang, G.; Gao, Y.; Tian, Z.; Yang, Z. Multifunctional phototheranostic nanomedicine for cancer imaging and treatment. Mater. Today Bio 2020, 5, 100035. [Google Scholar] [CrossRef]
- Man, F.; Lammers, T.; de Rosales, R.T.M. Imaging Nanomedicine-Based Drug Delivery: A Review of Clinical Studies. Mol. Imaging Biol. 2018, 20, 683–695. [Google Scholar] [CrossRef]
- Li, P.; Wang, D.; Hu, J.; Yang, X. The role of imaging in targeted delivery of nanomedicine for cancer therapy. Adv. Drug Deliv. Rev. 2022, 189, 114447. [Google Scholar] [CrossRef]
- Chen, W.; Schilperoort, M.; Cao, Y.; Shi, J.; Tabas, I.; Tao, W. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat. Rev. Cardiol. 2022, 19, 228–249. [Google Scholar] [CrossRef]
- Wu, P.-H.; Opadele, A.E.; Onodera, Y.; Nam, J.-M. Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy. Cancers 2019, 11, 1783. [Google Scholar] [CrossRef] [Green Version]
- Cano, A.; Turowski, P.; Ettcheto, M.; Duskey, J.T.; Tosi, G.; Sánchez-López, E.; García, M.L.; Camins, A.; Souto, E.B.; Ruiz, A.; et al. Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: From current to future challenges. J. Nanobiotechnol. 2021, 19, 122. [Google Scholar] [CrossRef] [PubMed]
- Thi, T.T.H.; Suys, E.J.A.; Lee, J.S.; Nguyen, D.H.; Park, K.D.; Truong, N.P. Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines 2021, 9, 359. [Google Scholar] [CrossRef]
- Patra, S.; Singh, M.; Wasnik, K.; Pareek, D.; Gupta, P.S.; Mukherjee, S.; Paik, P. Polymeric Nanoparticle Based Diagnosis and Nanomedicine for Treatment and Development of Vaccines for Cerebral Malaria: A Review on Recent Advancement. ACS Appl. Bio Mater. 2021, 4, 7342–7365. [Google Scholar] [CrossRef] [PubMed]
- Zhou, J.; Zhang, Z.; Joseph, J.; Zhang, X.; Ferdows, B.E.; Patel, D.N.; Chen, W.; Banfi, G.; Molinaro, R.; Cosco, D.; et al. Biomaterials and nanomedicine for bone regeneration: Progress and future prospects. Exploration 2021, 1, 20210011. [Google Scholar] [CrossRef]
- Garbayo, E.; Pascual-Gil, S.; Rodríguez-Nogales, C.; Saludas, L.; Estella-Hermoso de Mendoza, A.; Blanco-Prieto, M.J. Nanomedicine and drug delivery systems in cancer and regenerative medicine. WIREs Nanomed. Nanobiotechnol. 2020, 12, e1637. [Google Scholar] [CrossRef]
- Donahue, N.D.; Acar, H.; Wilhelm, S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv. Drug Deliv. Rev. 2019, 143, 68–96. [Google Scholar] [CrossRef]
- Rudramurthy, G.; Swamy, M.; Sinniah, U.; Ghasemzadeh, A. Nanoparticles: Alternatives Against Drug-Resistant Pathogenic Microbes. Molecules 2016, 21, 836. [Google Scholar] [CrossRef] [PubMed]
- Redhead, H.M.; Davis, S.S.; Illum, L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation. J. Control. Release 2001, 70, 353–363. [Google Scholar] [CrossRef]
- Truong, N.P.; Whittaker, M.R.; Mak, C.W.; Davis, T.P. The importance of nanoparticle shape in cancer drug delivery. Expert Opin. Drug Deliv. 2014, 12, 129–142. [Google Scholar] [CrossRef]
- Couvreur, P.; Barratt, G.; Fattal, E.; Vauthier, C. Nanocapsule Technology: A Review. Crit. Rev. Ther. Drug Carr. Syst. 2002, 19, 99–134. [Google Scholar] [CrossRef]
- Hui, Y.; Yi, X.; Hou, F.; Wibowo, D.; Zhang, F.; Zhao, D.; Gao, H.; Zhao, C.-X. Role of Nanoparticle Mechanical Properties in Cancer Drug Delivery. ACS Nano 2019, 13, 7410–7424. [Google Scholar] [CrossRef]
- Haque, S.T.; Chowdhury, E.H. Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles. Curr. Drug Deliv. 2018, 15, 485–496. [Google Scholar] [CrossRef]
- Qi, J.; Zhuang, J.; Lu, Y.; Dong, X.; Zhao, W.; Wu, W. In vivo fate of lipid-based nanoparticles. Drug Discov. Today 2017, 22, 166–172. [Google Scholar] [CrossRef]
- Paulis, L.E.; Geelen, T.; Kuhlmann, M.T.; Coolen, B.F.; Schäfers, M.; Nicolay, K.; Strijkers, G.J. Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J. Control. Release 2012, 162, 276–285. [Google Scholar] [CrossRef]
- Vinhas, R.; Mendes, R.; Fernandes, A.R.; Baptista, P.V. Nanoparticles—Emerging Potential for Managing Leukemia and Lymphoma. Front. Bioeng. Biotechnol. 2017, 5, 79. [Google Scholar] [CrossRef] [Green Version]
- Katsuki, S.; Matoba, T.; Koga, J.-i.; Nakano, K.; Egashira, K. Anti-inflammatory Nanomedicine for Cardiovascular Disease. Front. Cardiovasc. Med. 2017, 4, 87. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pascual-Gil, S.; Simón-Yarza, T.; Garbayo, E.; Prósper, F.; Blanco-Prieto, M.J. Cytokine-loaded PLGA and PEG-PLGA microparticles showed similar heart regeneration in a rat myocardial infarction model. Int. J. Pharm. 2017, 523, 531–533. [Google Scholar] [CrossRef]
- Oduk, Y.; Zhu, W.; Kannappan, R.; Zhao, M.; Borovjagin, A.V.; Oparil, S.; Zhang, J. VEGF nanoparticles repair the heart after myocardial infarction. Am. J. Physiol.-Heart Circ. Physiol. 2018, 314, H278–H284. [Google Scholar] [CrossRef] [PubMed]
- Danenberg, H.D.; Golomb, G.; Groothuis, A.; Gao, J.; Epstein, H.; Swaminathan, R.V.; Seifert, P.; Edelman, E.R. Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits. Circulation 2003, 108, 2798–2804. [Google Scholar] [CrossRef] [Green Version]
- Thomas, T.; Joice, M.; Sumit, M.; Silpe, J.; Kotlyar, A.; Bharathi, S.; Kukowska-Latallo, J.; Baker, J.; Choi, S. Design and In vitro Validation of Multivalent Dendrimer Methotrexates as a Folate-targeting Anticancer Therapeutic. Curr. Pharm. Des. 2013, 19, 6594–6605. [Google Scholar] [CrossRef] [Green Version]
- Singh, B.; Garg, T.; Goyal, A.K.; Rath, G. Recent advancements in the cardiovascular drug carriers. Artif. Cells Nanomed. Biotechnol. 2014, 44, 216–225. [Google Scholar] [CrossRef]
- Xue, X.; Shi, X.; Dong, H.; You, S.; Cao, H.; Wang, K.; Wen, Y.; Shi, D.; He, B.; Li, Y. Delivery of microRNA-1 inhibitor by dendrimer-based nanovector: An early targeting therapy for myocardial infarction in mice. Nanomed. Nanotechnol. Biol. Med. 2018, 14, 619–631. [Google Scholar] [CrossRef]
- Xu, Q.-H.; Guan, P.; Zhang, T.; Lu, C.; Li, G.; Liu, J.-X. Silver nanoparticles impair zebrafish skeletal and cardiac myofibrillogenesis and sarcomere formation. Aquat. Toxicol. 2018, 200, 102–113. [Google Scholar] [CrossRef]
- Zhang, W.; Zhang, Z.; Zhang, Y. The application of carbon nanotubes in target drug delivery systems for cancer therapies. Nanoscale Res. Lett. 2011, 6, 555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gorain, B.; Choudhury, H.; Pandey, M.; Kesharwani, P.; Abeer, M.M.; Tekade, R.K.; Hussain, Z. Carbon nanotube scaffolds as emerging nanoplatform for myocardial tissue regeneration: A review of recent developments and therapeutic implications. Biomed. Pharmacother. 2018, 104, 496–508. [Google Scholar] [CrossRef]
- Ahadian, S.; Davenport Huyer, L.; Estili, M.; Yee, B.; Smith, N.; Xu, Z.; Sun, Y.; Radisic, M. Moldable elastomeric polyester-carbon nanotube scaffolds for cardiac tissue engineering. Acta Biomater. 2017, 52, 81–91. [Google Scholar] [CrossRef]
- Sun, H.; Tang, J.; Mou, Y.; Zhou, J.; Qu, L.; Duval, K.; Huang, Z.; Lin, N.; Dai, R.; Liang, C.; et al. Carbon nanotube-composite hydrogels promote intercalated disc assembly in engineered cardiac tissues through β1-integrin mediated FAK and RhoA pathway. Acta Biomater. 2017, 48, 88–99. [Google Scholar] [CrossRef]
- Martinelli, V.; Cellot, G.; Toma, F.M.; Long, C.S.; Caldwell, J.H.; Zentilin, L.; Giacca, M.; Turco, A.; Prato, M.; Ballerini, L.; et al. Carbon Nanotubes Instruct Physiological Growth and Functionally Mature Syncytia: Nongenetic Engineering of Cardiac Myocytes. ACS Nano 2013, 7, 5746–5756. [Google Scholar] [CrossRef] [PubMed]
- Shin, S.R.; Jung, S.M.; Zalabany, M.; Kim, K.; Zorlutuna, P.; Kim, S.b.; Nikkhah, M.; Khabiry, M.; Azize, M.; Kong, J.; et al. Carbon-Nanotube-Embedded Hydrogel Sheets for Engineering Cardiac Constructs and Bioactuators. ACS Nano 2013, 7, 2369–2380. [Google Scholar] [CrossRef] [Green Version]
- Sun, H.; Zhou, J.; Huang, Z.; Qu, L.; Lin, N.; Liang, C.; Dai, R.; Tang, L.; Tian, F. Carbon nanotube-incorporated collagen hydrogels improve cell alignment and the performance of cardiac constructs. Int. J. Nanomed. 2017, 12, 3109–3120. [Google Scholar] [CrossRef] [Green Version]
- Sperling, R.A.; Rivera Gil, P.; Zhang, F.; Zanella, M.; Parak, W.J. Biological applications of gold nanoparticles. Chem. Soc. Rev. 2008, 37, 1896–1908. [Google Scholar] [CrossRef]
- Spivak, M.Y.; Bubnov, R.V.; Yemets, I.M.; Lazarenko, L.M.; Tymoshok, N.O.; Ulberg, Z.R. Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: A theranostic potential for PPP cardiology. EPMA J. 2013, 4, 20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahmed, S.M.; Abdelrahman, S.A.; Salama, A.E. Efficacy of gold nanoparticles against isoproterenol induced acute myocardial infarction in adult male albino rats. Ultrastruct. Pathol. 2017, 41, 168–185. [Google Scholar] [CrossRef]
- Paul, A.; Hasan, A.; Kindi, H.A.; Gaharwar, A.K.; Rao, V.T.S.; Nikkhah, M.; Shin, S.R.; Krafft, D.; Dokmeci, M.R.; Shum-Tim, D.; et al. Injectable Graphene Oxide/Hydrogel-Based Angiogenic Gene Delivery System for Vasculogenesis and Cardiac Repair. ACS Nano 2014, 8, 8050–8062. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Fan, W.; Wang, K.; Wei, H.; Zhang, R.; Wu, Y. Novel preparation of Au nanoparticles loaded Laponite nanoparticles/ECM injectable hydrogel on cardiac differentiation of resident cardiac stem cells to cardiomyocytes. J. Photochem. Photobiol. B Biol. 2019, 192, 49–54. [Google Scholar] [CrossRef]
- Zhu, K.; Wu, M.; Lai, H.; Guo, C.; Li, J.; Wang, Y.; Chen, Y.; Wang, C.; Shi, J. Nanoparticle-enhanced generation of gene-transfected mesenchymal stem cells for in vivo cardiac repair. Biomaterials 2016, 74, 188–199. [Google Scholar] [CrossRef]
- Skourtis, D.; Stavroulaki, D.; Athanasiou, V.; Fragouli, P.G.; Iatrou, H. Nanostructured Polymeric, Liposomal and Other Materials to Control the Drug Delivery for Cardiovascular Diseases. Pharmaceutics 2020, 12, 1160. [Google Scholar] [CrossRef]
- Fan, C.; Joshi, J.; Li, F.; Xu, B.; Khan, M.; Yang, J.; Zhu, W. Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease. Front. Bioeng. Biotechnol. 2020, 8, 687. [Google Scholar] [CrossRef]
- Vasan, R.S. Biomarkers of Cardiovascular Disease. Circulation 2006, 113, 2335–2362. [Google Scholar] [CrossRef]
- Lyngbakken, M.N.; Myhre, P.L.; Røsjø, H.; Omland, T. Novel biomarkers of cardiovascular disease: Applications in clinical practice. Crit. Rev. Clin. Lab. Sci. 2019, 56, 33–60. [Google Scholar] [CrossRef]
- McQueen, M.J.; Hawken, S.; Wang, X.; Ounpuu, S.; Sniderman, A.; Probstfield, J.; Steyn, K.; Sanderson, J.E.; Hasani, M.; Volkova, E.; et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case-control study. Lancet 2008, 372, 224–233. [Google Scholar] [CrossRef]
- The Emerging Risk Factors Collaboration. Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA 2009, 302, 1993–2000. [Google Scholar] [CrossRef] [Green Version]
- Movva, R.; Rader, D.J. Laboratory Assessment of HDL Heterogeneity and Function. Clin Chem. 2008, 54, 788–800. [Google Scholar] [CrossRef] [Green Version]
- Rosenson, R.S.; Brewer, H.B.; Ansell, B.; Barter, P.; Chapman, M.J.; Heinecke, J.W.; Kontush, A.; Tall, A.R.; Webb, N.R. Translation of High-Density Lipoprotein Function Into Clinical Practice. Circulation 2013, 128, 1256–1267. [Google Scholar] [CrossRef] [Green Version]
- Rink, J.S.; Sun, W.; Misener, S.; Wang, J.-J.; Zhang, Z.J.; Kibbe, M.R.; Dravid, V.P.; Venkatraman, S.; Thaxton, C.S. Nitric Oxide-Delivering High-Density Lipoprotein-like Nanoparticles as a Biomimetic Nanotherapy for Vascular Diseases. ACS Appl. Mater. Interfaces 2018, 10, 6904–6916. [Google Scholar] [CrossRef]
- Foit, L.; Thaxton, C.S. Synthetic high-density lipoprotein-like nanoparticles potently inhibit cell signaling and production of inflammatory mediators induced by lipopolysaccharide binding Toll-like receptor 4. Biomaterials 2016, 100, 67–75. [Google Scholar] [CrossRef]
- Chen, W.; Cormode, D.P.; Fayad, Z.A.; Mulder, W.J.M. Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. WIREs Nanomed. Nanobiotechnol. 2011, 3, 146–161. [Google Scholar] [CrossRef]
- Leeper, N.J.; Park, S.-m.; Smith, B.R. High-Density Lipoprotein Nanoparticle Imaging in Atherosclerotic Vascular Disease. J. Am. Coll. Cardiol. Basic Trans Sci. 2017, 2, 98–100. [Google Scholar] [CrossRef]
- Ponthieux, A.; Herbeth, B.; Droesch, S.; Haddy, N.; Lambert, D.; Visvikis, S. Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: The Stanislas study. Atherosclerosis 2004, 172, 299–308. [Google Scholar] [CrossRef]
- Hwang, S.-J.; Ballantyne, C.M.; Sharrett, A.R.; Smith, L.C.; Davis, C.E.; Gotto, A.M.; Boerwinkle, E. Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases. Circulation 1997, 96, 4219–4225. [Google Scholar] [CrossRef]
- Caterina, R.D.; Basta, G.; Lazzerini, G.; Dell’Omo, G.; Petrucci, R.; Morale, M.; Carmassi, F.; Pedrinelli, R. Soluble Vascular Cell Adhesion Molecule-1 as a Biohumoral Correlate of Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2646–2654. [Google Scholar] [CrossRef]
- Iiyama, K.; Hajra, L.; Iiyama, M.; Li, H.; DiChiara, M.; Medoff, B.D.; Cybulsky, M.I. Patterns of Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1 Expression in Rabbit and Mouse Atherosclerotic Lesions and at Sites Predisposed to Lesion Formation. Circ. Res. 1999, 85, 199–207. [Google Scholar] [CrossRef]
- Li, H.; Cybulsky, M.I.; Gimbrone Jr, M.A.; Libby, P. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am. J. Pathol. 1993, 143, 1551. [Google Scholar]
- Cybulsky, M.I.; Iiyama, K.; Li, H.; Zhu, S.; Chen, M.; Iiyama, M.; Davis, V.; Gutierrez-Ramos, J.-C.; Connelly, P.W.; Milstone, D.S. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Investig. 2001, 107, 1255–1262. [Google Scholar] [CrossRef] [Green Version]
- Nakashima, Y.; Raines, E.W.; Plump, A.S.; Breslow, J.L.; Ross, R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 842–851. [Google Scholar] [CrossRef] [Green Version]
- Nahrendorf, M.; Jaffer, F.A.; Kelly, K.A.; Sosnovik, D.E.; Aikawa, E.; Libby, P.; Weissleder, R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114, 1504–1511. [Google Scholar] [CrossRef] [Green Version]
- Attia, M.F.; Anton, N.; Wallyn, J.; Omran, Z.; Vandamme, T.F. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J. Pharm. Pharmacol. 2019, 71, 1185–1198. [Google Scholar] [CrossRef] [Green Version]
- Alavi, M.; Hamidi, M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab. Pers. Ther. 2019, 34, 20180032. [Google Scholar] [CrossRef]
- Villa-Roel, N.; Gu, L.; Fernandez Esmerats, J.; Kang, D.-W.; Kumar, S.; Jo, H. Hypoxia Inducible Factor-1α Inhibitor, PX-478, Reduces Atherosclerosis in vivo. Arterioscler. Thromb. Vasc. Biol. 2020, 40, A366. [Google Scholar]
- Kumar, S.; Kim, C.W.; Simmons, R.D.; Jo, H. Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: Mechanosensitive athero-miRs. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 2206–2216. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kumar, S.; Kim, C.W.; Son, D.J.; Ni, C.W.; Jo, H. Flow-dependent regulation of genome-wide mRNA and microRNA expression in endothelial cells in vivo. Sci. Data 2014, 1, 140039. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mudau, M.; Genis, A.; Lochner, A.; Strijdom, H. Endothelial dysfunction: The early predictor of atherosclerosis. Cardiovasc. J. Afr. 2012, 23, 222–231. [Google Scholar] [CrossRef]
- Chiu, J.-J.; Chien, S. Effects of disturbed flow on vascular endothelium: Pathophysiological basis and clinical perspectives. Physiol. Rev. 2011, 91, 327–387. [Google Scholar] [CrossRef] [Green Version]
- Cybulsky, M.I.; Gimbrone, M.A. Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis. Science 1991, 251, 788–791. [Google Scholar] [CrossRef] [Green Version]
- Dong, Z.M.; Chapman, S.M.; Brown, A.A.; Frenette, P.S.; Hynes, R.O.; Wagner, D.D. The combined role of P- and E-selectins in atherosclerosis. J. Clin. Investig. 1998, 102, 145–152. [Google Scholar] [CrossRef] [Green Version]
- Collins, R.G.; Velji, R.; Guevara, N.V.; Hicks, M.J.; Chan, L.; Beaudet, A.L. P-Selectin or Intercellular Adhesion Molecule (Icam)-1 Deficiency Substantially Protects against Atherosclerosis in Apolipoprotein E–Deficient Mice. J. Exp. Med. 2000, 191, 189–194. [Google Scholar] [CrossRef]
- Claesson-Welsh, L.; Dejana, E.; McDonald, D.M. Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies. Trends Mol. Med. 2021, 27, 314–331. [Google Scholar] [CrossRef]
- Kim, H.; Han, J.; Park, J.-H. Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity. J. Control. Release 2020, 319, 77–86. [Google Scholar] [CrossRef]
- Zimmer, S.; Grebe, A.; Bakke, S.S.; Bode, N.; Halvorsen, B.; Ulas, T.; Skjelland, M.; De Nardo, D.; Labzin, L.I.; Kerksiek, A. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci. Transl. Med. 2016, 8, 333ra50. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.; Kumar, S.; Kang, D.-W.; Jo, H.; Park, J.-H. Affinity-Driven Design of Cargo-Switching Nanoparticles to Leverage a Cholesterol-Rich Microenvironment for Atherosclerosis Therapy. ACS Nano 2020, 14, 6519–6531. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, K.D.; Allen, M.D.; McDonald, T.O.; Chait, A.; Harlan, J.M.; Fishbein, D.; McCarty, J.; Ferguson, M.; Hudkins, K.; Benjamin, C.D.; et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J. Clin. Investig. 1993, 92, 945–951. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Distasio, N.; Salmon, H.; Dierick, F.; Ebrahimian, T.; Tabrizian, M.; Lehoux, S. VCAM-1-Targeted Gene Delivery Nanoparticles Localize to Inflamed Endothelial Cells and Atherosclerotic Plaques. Adv. Ther. 2021, 4, 2000196. [Google Scholar] [CrossRef]
- Kheirolomoom, A.; Kim, C.W.; Seo, J.W.; Kumar, S.; Son, D.J.; Gagnon, M.K.J.; Ingham, E.S.; Ferrara, K.W.; Jo, H. Multifunctional nanoparticles facilitate molecular targeting and miRNA delivery to inhibit atherosclerosis in ApoE−/− mice. ACS Nano 2015, 9, 8885–8897. [Google Scholar] [CrossRef]
- Xu, W.; Zhang, S.; Zhou, Q.; Chen, W. VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions. Artif. Cells Nanomed. Biotechnol. 2019, 47, 2440–2448. [Google Scholar] [CrossRef] [Green Version]
- Yadav, M.; Bhayana, S.; Liu, J.; Lu, L.; Huang, J.; Ma, Y.; Qamri, Z.; Mo, X.; Jacob, D.S.; Parasa, S.T.; et al. Two-miRNA-based finger-stick assay for estimation of absorbed ionizing radiation dose. Sci. Transl. Med. 2020, 12, eaaw5831. [Google Scholar] [CrossRef]
- Nam, D.; Ni, C.-W.; Rezvan, A.; Suo, J.; Budzyn, K.; Llanos, A.; Harrison, D.; Giddens, D.; Jo, H. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2009, 297, H1535–H1543. [Google Scholar] [CrossRef]
- Kumar, S.; Kang, D.W.; Rezvan, A.; Jo, H. Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation. Lab. Investig. 2017, 97, 935–945. [Google Scholar] [CrossRef] [Green Version]
- Boada, C.; Zinger, A.; Tsao, C.; Zhao, P.; Martinez, J.O.; Hartman, K.; Naoi, T.; Sukhoveshin, R.; Sushnitha, M.; Molinaro, R.; et al. Rapamycin-Loaded Biomimetic Nanoparticles Reverse Vascular Inflammation. Circ. Res. 2020, 126, 25–37. [Google Scholar] [CrossRef]
- Mita, M.M.; Mita, A.; Rowinsky, E.K. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. 2003, 2, 168–176. [Google Scholar] [CrossRef]
- Tsang, C.K.; Qi, H.; Liu, L.F.; Zheng, X.S. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 2007, 12, 112–124. [Google Scholar] [CrossRef]
- Wu, G.; Wei, W.; Zhang, J.; Nie, W.; Yuan, L.; Huang, Y.; Zuo, L.; Huang, L.; Xi, X.; Xie, H.Y. A self-driven bioinspired nanovehicle by leukocyte membrane-hitchhiking for early detection and treatment of atherosclerosis. Biomaterials 2020, 250, 119963. [Google Scholar] [CrossRef]
- Song, Y.; Zhang, N.; Li, Q.; Chen, J.; Wang, Q.; Yang, H.; Tan, H.; Gao, J.; Dong, Z.; Pang, Z.; et al. Biomimetic liposomes hybrid with platelet membranes for targeted therapy of atherosclerosis. Chem. Eng. J. 2021, 408, 127296. [Google Scholar] [CrossRef]
- Kaplan, R.N.; Riba, R.D.; Zacharoulis, S.; Bramley, A.H.; Vincent, L.; Costa, C.; MacDonald, D.D.; Jin, D.K.; Shido, K.; Kerns, S.A.; et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438, 820–827. [Google Scholar] [CrossRef]
Drug Type | Loaded Drug | Nanoplatforms | Disorders | Mechanism of Action | Surface Modifications | Model of Use/Animal | Administration Route |
---|---|---|---|---|---|---|---|
Statins | atorvastatin atorvastatin | HA-ATV-NP Oxi-COS/MM-AT-nps | atherosclerosis atherosclerosis | suppression of inflammation suppression of inflammation | hyaluronan proteins derived from macrophages membrane | in vitro; in vivo, ApoE-/- mice in vitro; in vivo, ApoE-/- mice | intravenous injection intravenous injection |
Rapamycin | rapamycin rapamycin | PFN1-CD-mnps liposome | atherosclerosis atherosclerosis | suppression of inflammation suppression of inflammation | profilin-1 antibody membrane protein from leukocytes | in vitro; in vivo, ApoE-/- mice in vitro; in vivo, ApoE-/- mice | intravenous injection retro-orbital injection |
Traditional Chinese medicine | Sal B, PNS | RGD-S/P-lpns | AMI | RGD peptide ligand | in vivo, SD rats receiving experimental MI | intravenous injection | |
Small molecule agonists/inhibitors | SMI 6877002 | rHDL NPs | atherosclerosis | inhibition of monocyte recruitment; suppression of plaque inflammation | ApoA-I | in vitro; in vivo, ApoE-/- mice, cynomolgus monkeys | intravenous injection |
Small molecule agonists/inhibitors | SNO | SNO-HDL NPs | atherosclerosis | ApoA-I | in vitro; in vivo, ApoE-/- mice | intravenous injection | |
siRNA | siCamk2g | G0-C14 PLGA NPs | atherosclerosis | promotion of efferocytosis | S2P peptide (CRTLTVRKC) | in vitro; in vivo, Ldlr-/- mice | intravenous injection |
miRNA | miR-145 | PAM | atherosclerosis | promotion of the contractile VSMC phenotype | MCP1/CCL2 | in vitro; in vivo, ApoE-/- mice | intravenous injection |
miRNA switches | miRNA switches | mRNA-p5RHH nanoparticle | restenosis | specific inhibition of the VSMCs and inflammatory cells | in vitro; in vivo, C57BL6/J mice undergoing femoral artery wire injury | intravenous injection |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Choi, K.-A.; Kim, J.H.; Ryu, K.; Kaushik, N. Current Nanomedicine for Targeted Vascular Disease Treatment: Trends and Perspectives. Int. J. Mol. Sci. 2022, 23, 12397. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232012397
Choi K-A, Kim JH, Ryu K, Kaushik N. Current Nanomedicine for Targeted Vascular Disease Treatment: Trends and Perspectives. International Journal of Molecular Sciences. 2022; 23(20):12397. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232012397
Chicago/Turabian StyleChoi, Kyung-A, June Hyun Kim, Kitae Ryu, and Neha Kaushik. 2022. "Current Nanomedicine for Targeted Vascular Disease Treatment: Trends and Perspectives" International Journal of Molecular Sciences 23, no. 20: 12397. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232012397